MedTrace Logo

Creatine Safety & Tolerability in Huntington's Disease

NCT01412151 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-03-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to extend findings from the creatine dose-finding study (CREST-UP1) in Huntington's disease to evaluate the long-term safety, tolerability, and clinical impact of high dose creatine.

Conditions

  • Huntington's Disease (HD)

Interventions

DRUG

Creatine monohydrate

Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Diana Rosas, MD, MS · Massachusetts General Hospital

  • Steven M Hersch, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01412151 on ClinicalTrials.gov